#1
#1 out of 1
health4h ago
Abeona Therapeutics reports constructive Pre-IND meeting with FDA on ABO-701, IND targeted for 2027
- Abeona Therapeutics says the June 3 Pre-IND meeting with the FDA on ABO-701 was constructive and keeps the 2027 IND target.
- The PRE-IND meeting focused on ABO-701, a PC-targeted engineered T-cell therapy for prostate cancer.
- No official meeting minutes have been released yet by the FDA.
- ABO-701's IND timing depends on FDA feedback, preclinical results, manufacturing and funding.
- Abeona reaffirmed its plan to submit the ABO-701 IND in 2027.
- The report contextualizes the news within Abeona's broader development strategy for ABO-701.
- The summary notes that the information is based on AI-generated content and SEC filings.
- Abeona's ABO-701 targets PSMA for potential prostate cancer therapy.
- The news is categorized under TradingView US stocks coverage.
Vote 0